Kite Pharma Discloses CAR-T Patient Death, Rattling Investors – TheStreet.com
TheStreet.com |
Kite Pharma Discloses CAR–T Patient Death, Rattling Investors
TheStreet.com CAR-T is a new form of cancer immunotherapy in which a patient's own T cells are removed and then engineered to identify and kill malignant blood cancer cells. CAR-T is highly effective at eliminating cancer cells in patients no longer responsive to … Kite Pharma Inc (NASDAQ:KITE) reported earnings of ($1.28) per share missing Walls Streets expectations. |
